Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide versus conventional non-steroidal antiandrogen with androgen deprivation for metastatic prostate cancer
ACTRN12614000110684Phase 3Active, not recruiting
- Sponsor
- NHMRC Clinical Trials Centre
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of enzalutamide, bicalutamide, nilutamide and flutamide in prostate cancer (PCa) and Metastatic Prostate Cancer (mPC) (2 arms), sponsored by NHMRC Clinical Trials Centre. Primary endpoint: Overall survival. Started Mar 2014; status: active, not recruiting.
02
Drugs
enzalutamidebicalutamidenilutamideflutamide
03
Conditions
prostate cancer (PCa)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on ACTRN12614000110684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000110684.